Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Long-Term Debt Repayments (2016 - 2022)

Sonoma Pharmaceuticals (SNOA) has 4 years of Long-Term Debt Repayments data on record, last reported at $575000.0 in Q1 2013.

  • For Q1 2013, Long-Term Debt Repayments rose 92.31% year-over-year to $575000.0; the TTM value through Mar 2013 reached $2.1 million, up 78.95%, while the annual FY2023 figure was $120000.0, 300.0% up from the prior year.
  • Long-Term Debt Repayments reached $575000.0 in Q1 2013 per SNOA's latest filing, up from $534000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $575000.0 in Q1 2013 and bottomed at $54000.0 in Q4 2010.
  • Average Long-Term Debt Repayments over 4 years is $304750.0, with a median of $294500.0 recorded in 2011.
  • Peak YoY movement for Long-Term Debt Repayments: soared 437.04% in 2011, then skyrocketed 43.75% in 2012.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $54000.0 in 2010, then skyrocketed by 437.04% to $290000.0 in 2011, then skyrocketed by 84.14% to $534000.0 in 2012, then rose by 7.68% to $575000.0 in 2013.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $575000.0 in Q1 2013, $534000.0 in Q4 2012, and $507000.0 in Q3 2012.